Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.50 |
| ▸ | DPP4 | P27487 | 3/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31686089 | 0.82 | TAAR1 (0.54) | PNMTDPP4TAAR1LOXL2CYP1A2 | |
| SCHEMBL4950688 | 0.82 | TAAR1 (0.54) | PNMTDPP4TAAR1LOXL2CYP1A2 | |
| SCHEMBL9862093 | 0.80 | HSPA5 (0.40) | PNMTTAAR1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL4170188 | 0.78 | TRPA1 (0.36) | PNMTCYP1A1CYP1A2CYP1B1PYCR1 | |
| SCHEMBL4953056 | 0.76 | GABRA1 (0.46) | CYP2A6PYCR1 | |
| SCHEMBL1253891 | 0.76 | CYP1A1 (0.33) | PNMTCYP1A1CYP1A2CYP1B1PYCR1 | |
| SCHEMBL149728 | 0.76 | APOBEC3G (0.43) | CYP1A1CYP1A2CYP1B1CYP2A6PYCR1 | |
| SCHEMBL20838091 | 0.76 | CYP1A1 (0.33) | PNMTCYP1A1CYP1A2CYP1B1PYCR1 | |
| SCHEMBL1110228 | 0.76 | CYP19A1 (0.46) | PNMTDPP4LOXL2CYP1A2 | |
| SCHEMBL6679575 | 0.76 | IDO1 (0.50) | PNMTCYP1A1CYP1A2CYP1B1PYCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2510925-B1 | Small-Molecule modulators of TRP-P8 activity | DENDREON CORP (US) | 2016-07-20 | — | — | EP | claimed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| CN-103168022-B | Prepare the method for propynoic acid or derivatives thereof | BASF SE (DE) | 2016-02-17 | — | — | CN | disclosed |
| CN-103168022-A | Process for preparing a propiolic acid or a derivative thereof | BASF SE | 2013-06-19 | — | — | CN | disclosed |
| CN-101600715-A | Compound with angiotensin-ii receptor antagonistic action and PPAR γ activating activities | PFIZER PROD INC (US) | 2009-12-09 | — | — | CN | disclosed |
| EP-2065382-A1 | CGRP antagonists | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-06-03 | — | — | EP | disclosed |
| WO-2009050235-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | PNMT 4258/4885DPP4 2352/4885TAAR1 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.